3Daughters
Private Company
Funding information not available
Overview
3Daughters is a private, preclinical-stage biotech company developing a disruptive, integrated uterine drug delivery system starting with a next-generation IUD. Its core innovation is a frameless, non-hormonal IUD composed of three magnetic copper ellipses that self-assemble in the uterus, paired with a patented Slider™ inserter/retriever system designed to reduce insertion pain and eliminate removal strings. The company is targeting the large and growing U.S. IUD market, with plans to file an IND and initiate Phase 1 trials in 2025, supported by a current Series A fundraising round of $15M.
Technology Platform
Integrated uterine drug delivery system featuring a frameless, non-hormonal, magnetic copper IUD that self-assembles in the uterus, paired with proprietary Slider™ inserter and retriever devices designed to reduce procedural pain and eliminate removal strings.
Opportunities
Risk Factors
Competitive Landscape
The IUD market is dominated by large players like Bayer (hormonal IUDs) and CooperSurgical (copper IUD Paragard), whose T-shaped devices are the standard of care. 3Daughters' main competitive advantage is its focus on reducing procedural pain and eliminating strings, a direct response to the key shortcomings of these established products.